<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35118666</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-9071</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>94</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of medical virology</Title>
          <ISOAbbreviation>J Med Virol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Omicron (B.1.1.529) variant of SARS-CoV-2: Concerns, challenges, and recent updates.</ArticleTitle>
        <Pagination>
          <StartPage>2336</StartPage>
          <EndPage>2342</EndPage>
          <MedlinePgn>2336-2342</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.27633</ELocationID>
        <Abstract>
          <AbstractText>Omicron has shown immune escape from neutralizing antibodies generated through previous infection or vaccination. It could evade the protection provided by mAbs being used in clinics for treating coronavirus disease 2019 (COVID‐19) patients. Booster dose is recommended to elevate the protective levels of antibodies in COVID‐19 vaccinated individuals. The development of powerful oral antiviral drugs such as Molnupiravir and Paxlovid have shown promising clinical results and raised new hopes of COVID‐19 treatment. High efforts are being made to develop highly efficacious vaccines, and by implementing appropriate prevention and control strategies to counter Omicron.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mohapatra</LastName>
            <ForeName>Ranjan K</ForeName>
            <Initials>RK</Initials>
            <Identifier Source="ORCID">0000-0001-7623-3343</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Government College of Engineering, Keonjhar, Odisha, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tiwari</LastName>
            <ForeName>Ruchi</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0001-7763-5547</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Veterinary Microbiology and Immunology, College of Veterinary Sciences, Uttar Pradesh Pandit Deen Dayal Upadhyaya PashuChikitsa Vigyan Vishwavidyalaya Evam Go Anusandhan Sansthan (DUVASU), Mathura, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sarangi</LastName>
            <ForeName>Ashish K</ForeName>
            <Initials>AK</Initials>
            <Identifier Source="ORCID">0000-0002-5602-4736</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, School of Applied Sciences, Centurion University of Technology and Management, Odisha, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Islam</LastName>
            <ForeName>Md Rabiul</ForeName>
            <Initials>MR</Initials>
            <Identifier Source="ORCID">0000-0003-2820-3144</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chakraborty</LastName>
            <ForeName>Chiranjib</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-3958-239X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dhama</LastName>
            <ForeName>Kuldeep</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0001-7469-4752</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Med Virol</MedlineTA>
        <NlmUniqueID>7705876</NlmUniqueID>
        <ISSNLinking>0146-6615</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>55</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35118666</ArticleId>
        <ArticleId IdType="pmc">PMC9015506</ArticleId>
        <ArticleId IdType="doi">10.1002/jmv.27633</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
World Health Organization (WHO)
. WHO COVID‐19 Dashboard ‐ Up to date data on pandemic. Accessed January 24, 2022. https://covid19.who.int/?gclid=CjwKCAiA65iBBhB-EiwAW253W0GZ9U6TBkdh4YsVuarVQDugzsyLRuZF-ctQMSaXK8Lcz9kZ14J9kRoC7uAQAvD_BwE
</Citation>
        </Reference>
        <Reference>
          <Citation>
Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L. Geneva Centre for Emerging Viral Diseases. Novel SARS‐CoV‐2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021;27(8):1109‐1117. 10.1016/j.cmi.2021.05.022
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmi.2021.05.022</ArticleId>
            <ArticleId IdType="pmc">PMC8127517</ArticleId>
            <ArticleId IdType="pubmed">34015535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
GISAID
. Tracking of variants. Accessed January 24,  2022. https://www.gisaid.org/hcov19-variants
</Citation>
        </Reference>
        <Reference>
          <Citation>
Thaku2r V, Bhola S, Thakur P, et al. Waves and variants of SARS‐CoV‐2: understanding the causes and effect of the COVID‐19 catastrophe. Infection. 2021:1‐16. 10.1007/s15010-021-01734-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s15010-021-01734-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
WHO
. World Health Organization. Tracking SARS‐CoV‐2 variants, 2021. Accessed January 24, 2022. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
</Citation>
        </Reference>
        <Reference>
          <Citation>
WHO
. DRAFT landscape of COVID‐19 candidate vaccines. Accessed January 24,   2022. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
</Citation>
        </Reference>
        <Reference>
          <Citation>
ECDC
. Accessed on January 24, 2022. https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-2-data-20-january-2022
</Citation>
        </Reference>
        <Reference>
          <Citation>
Kannan S, Shaik Syed Ali P, Sheeza A. Omicron (B.1.1.529) ‐ variant of concern ‐ molecular profile and epidemiology: a mini review. Eur Rev Med Pharmacol Sci. 2021;25(24):8019‐8022. 10.26355/eurrev_202112_276532021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.26355/eurrev_202112_27653</ArticleId>
            <ArticleId IdType="pubmed">34982466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Meo SA, Meo AS, Al‐Jassir FF, Klonoff DC. Omicron SARS‐CoV‐2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 2021;25(24):8012‐8018. 10.26355/eurrev_202112_27652
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.26355/eurrev_202112_27652</ArticleId>
            <ArticleId IdType="pubmed">34982465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mohapatra RK, Sarangi AK, Kandi V, Azam M, Tiwari R, Dhama K. Omicron (B.1.1.529 variant of SARS‐CoV‐2); an emerging threat: current global scenario. J Med Virol. 2021. 10.1002/jmv.27561
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.27561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
World Health Organization (WHO)
. Classification of Omicron (B.1.1.529): SARS‐CoV‐2 Variant of Concern, November 26,  2021. Accessed December 30, 2021. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
</Citation>
        </Reference>
        <Reference>
          <Citation>
Scott L, Hsiao NY, Moyo S, et al. Track Omicron's spread with molecular data. Science. 2021; 374(6574):1454‐1455. 10.1126/science.abn4543
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abn4543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Del Rio C, Omer SB, Malani PN. Winter of Omicron‐the evolving COVID‐19 pandemic. JAMA. 2021;327:319‐320. 10.1001/jama.2021.24315
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.24315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Worldmeter COVID‐19 Coronavirus pandemic. Accessed January 24, 2022. https://www.worldometers.info/coronavirus/
</Citation>
        </Reference>
        <Reference>
          <Citation>
Christie B. Covid‐19: Early studies give hope omicron is milder than other variants. BMJ. 2021;375:n3144. 10.1136/bmj.n3144
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n3144</ArticleId>
            <ArticleId IdType="pubmed">34949600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dyer O. Covid‐19: Omicron is causing more infections but fewer hospital admissions than delta, South African data show. BMJ. 2021;375:n3104. 10.1136/bmj.n3104
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n3104</ArticleId>
            <ArticleId IdType="pubmed">34916213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Iacobucci G. Covid‐19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show. BMJ. 2021;375:n3103. 10.1136/bmj.n3103
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n3103</ArticleId>
            <ArticleId IdType="pubmed">34916215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mahase E. Covid‐19: Hospital admission 50‐70% less likely with omicron than delta, but transmission a major concern. BMJ. 2021;24(375):n3151. 10.1136/bmj.n3151
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n3151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen J, Wang R, Gilby NB, Wei GW. Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62:412‐422. 10.1021/acs.jcim.1c01451
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jcim.1c01451</ArticleId>
            <ArticleId IdType="pmc">PMC8751645</ArticleId>
            <ArticleId IdType="pubmed">34989238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ito K, Piantham C, Nishiura H. Relative instantaneous reproduction number of Omicron SARS‐CoV‐2 variant with respect to the Delta variant in Denmark. J Med Virol. 2021. 10.1002/jmv.27560
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.27560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lupala CS, Ye Y, Chen H, Su XD, Liu H. Mutations on RBD of SARS‐CoV‐2 Omicron variant result in stronger binding to human ACE2 receptor. Biochem Biophys Res Commun. 2021;590:34‐41. 10.1016/j.bbrc.2021.12.079
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2021.12.079</ArticleId>
            <ArticleId IdType="pmc">PMC8702632</ArticleId>
            <ArticleId IdType="pubmed">34968782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Financial Express, What exactly is ‘Delmicron'? Scientists warn of super strain — Here's all about its origin, mutation, etc. December 28, 2021. https://www.financialexpress.com/lifestyle/health/what-exactly-is-delmicron-scientists-warn-of-super-strain-heres-all-about-its-origin-mutation-etc/2389547/
</Citation>
        </Reference>
        <Reference>
          <Citation>The Times of India, COVID‐19 variant: What is Delmicron and how is it different from Omicron? December 27, 2021. https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/covid-19-variant-what-is-delmicron-and-how-is-it-different-from-omicron/photostory/88472473.cms
</Citation>
        </Reference>
        <Reference>
          <Citation>IT News, (G. Bhalla), Delta plus Omicron are driving COVID surge now, know symptoms, mortality rate, January 04, 2022. https://www.indiatimes.com/news/india/omicron-delmicron-west-us-europe-557582.html
</Citation>
        </Reference>
        <Reference>
          <Citation>WION, After ‘Delmicron', it's ‘flurona': Israel reports first double infection of Covid and flu, December 31, 2021, https://www.wionews.com/world/after-delmicron-its-flurona-israel-reports-first-double-infection-of-covid-and-flu-441504
</Citation>
        </Reference>
        <Reference>
          <Citation>The Economic Times, All you need to know about Florona: A double infection of flu and COVID‐19, January 02, 2022. https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/all-you-need-to-know-about-florona-a-double-infection-of-flu-and-covid-19/articleshow/88647407.cms?from=mdr
</Citation>
        </Reference>
        <Reference>
          <Citation>
Khaleej Times
, From Delmicron to flurona: Israel reports first double infection of Covid and flu, December 31,  2021. Accessed January 5, 2022. https://www.khaleejtimes.com/coronavirus/israel-reports-first-double-infection-of-covid-and-flu
</Citation>
        </Reference>
        <Reference>
          <Citation>
Time
, WHO Official Downplays New COVID IHU Variant Found in France, January 4, 2022. Accessed January 5, 2022. https://time.com/6133106/ihu-new-covid-variant/
</Citation>
        </Reference>
        <Reference>
          <Citation>
India Today
. Study claims ‘Delmicron' threat less likely for now, January 2, 2022. Accessed January 6, 2022. https://www.indiatoday.in/coronavirus-outbreak/story/study-claims-delmicron-threat-less-likely-1895177-2022-01-02
</Citation>
        </Reference>
        <Reference>
          <Citation>
Fahim M, El Sood Ghonim HA, Roshdy WH, et al. Coinfection with SARS‐CoV‐2 and influenza A(H1N1) in a patient seen at an influenza‐like illness surveillance site in Egypt: case report. JMIR Public Health Surveill. 2021;7(4):e27433. 10.2196/27433
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2196/27433</ArticleId>
            <ArticleId IdType="pmc">PMC8081026</ArticleId>
            <ArticleId IdType="pubmed">33784634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
WHO
. Coronavirus disease (COVID‐19): Similarities and differences between COVID‐19 and Influenza, September 30, 2021. Accessed January 5, 2022. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/coronavirus-disease-covid-19-similarities-and-differences-with-influenza#
</Citation>
        </Reference>
        <Reference>
          <Citation>CNN (H. Yan), Yes, you can have Covid‐19 and the flu at the same time. Here's what that could look like. September 29, 2021. Accessed January 5, 2022. https://edition.cnn.com/2021/09/29/health/covid-flu-same-time/index.html
</Citation>
        </Reference>
        <Reference>
          <Citation>
The Times of India
, France detects new Covid variant IHU, 12 infected, January 4, 2022. Accessed January 6, 2022. https://timesofindia.indiatimes.com/world/europe/france-detects-new-covid-variant-ihu-12-infected/articleshow/88684678.cms
</Citation>
        </Reference>
        <Reference>
          <Citation>
Colson P, Delerce J, Burel E, et al. Emergence in Southern France of a new SARS‐CoV‐2 variant of probably Cameroonian 5 origin harbouring both substitutions N501Y and E484K in the spike protein, medRxiv [preprint] 2022. 10.1101/2021.12.24.21268174
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.12.24.21268174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS‐CoV‐2 variant Delta to antibody neutralization. Nature. 2021;596:276‐280. 10.1038/s41586-021-03777-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03777-9</ArticleId>
            <ArticleId IdType="pubmed">34237773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS‐CoV‐2 Omicron antigenic shift. Nature. 2021. 10.1038/s41586-021-04386-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-04386-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Davis C, Logan N, Tyson G, et al. Reduced neutralisation of the Delta (B.1.617.2) SARS‐CoV‐2 variant of concern following vaccination. PLoS Pathog. 2021;17(12):e1010022. 10.1371/journal.ppat.1010022
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1010022</ArticleId>
            <ArticleId IdType="pmc">PMC8639073</ArticleId>
            <ArticleId IdType="pubmed">34855916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang Y, Zhang L, Li Q, et al. The significant immune escape of pseudotyped SARS‐CoV‐2 variant Omicron. Emerg Microbes Infect. 2022;11(1):1‐5. 10.1080/22221751.2021.2017757
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/22221751.2021.2017757</ArticleId>
            <ArticleId IdType="pmc">PMC8725892</ArticleId>
            <ArticleId IdType="pubmed">34890524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS‐CoV‐2 Omicron variant neutralization in serum from vaccinated and convalescent persons. N Engl J Med. Published online January 12, 2022. 10.1056/NEJMc2119236
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2119236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mlcochova P, Kemp SA, Dhar MS, et al. SARS‐CoV‐2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599:114‐119. 10.1038/s41586-021-03944-y
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03944-y</ArticleId>
            <ArticleId IdType="pmc">PMC8566220</ArticleId>
            <ArticleId IdType="pubmed">34488225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang B, Goh YS, Fong SW, et al. Resistance of SARS‐CoV‐2 Delta variant to neutralization by BNT162b2‐elicited antibodies in Asians. Lancet Reg Health West Pac. 2021;15:100276. 10.1016/j.lanwpc.2021.100276
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lanwpc.2021.100276</ArticleId>
            <ArticleId IdType="pmc">PMC8450274</ArticleId>
            <ArticleId IdType="pubmed">34568853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lu L, Mok BW, Chen LL, et al. Neutralization of SARS‐CoV‐2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin Infect Dis. 2021:ciab1041. 10.1093/cid/ciab1041
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciab1041</ArticleId>
            <ArticleId IdType="pmc">PMC8754807</ArticleId>
            <ArticleId IdType="pubmed">34915551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cele S, Jackson L, Khan K. SARS‐CoV‐2 omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. https://www.ahri.org/wp-content/uploads/2021/12/MEDRXIV-2021-267417v1-Sigal.pdf; 10.1101/2021.12.08.21267417
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.12.08.21267417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization of the SARS‐CoV‐2 Omicron variant. N Engl J Med. Published online December 30, 2021. 10.1056/NEJMc2119641
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2119641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of protection against SARS‐CoV‐2 variants and the impact of boosting: a meta‐analysis. Lancet Microbe. 2022;3(1):e52‐e61. 10.1016/S2666-5247(21)00267-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2666-5247(21)00267-6</ArticleId>
            <ArticleId IdType="pmc">PMC8592563</ArticleId>
            <ArticleId IdType="pubmed">34806056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nielsen C, Wiid Svarrer C, Bybjerg‐Grauholm J, et al. Epidemiological characterisation of the first 785 SARS‐CoV‐2 Omicron variant cases in Denmark, December 2021. Euro Surveill. 2021;26(50), 10.2807/1560-7917.ES.2021.26.50.2101146
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.50.2101146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sievers BL, Chakraborty S, Xue Y, et al. Antibodies elicited by SARS‐CoV‐2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci Transl Med. 2022:eabn7842. 10.1126/scitranslmed.abn7842
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.abn7842</ArticleId>
            <ArticleId IdType="pmc">PMC8891085</ArticleId>
            <ArticleId IdType="pubmed">35025672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Garcia‐Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA‐based COVID‐19 vaccine boosters induce neutralizing immunity against SARS‐CoV‐2 Omicron variant. Cell. Published online January 6, 2022. 10.1016/j.cell.2021.12.033
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2021.12.033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bates TA, McBride SK, Winders B, et al. Antibody response and variant cross‐neutralization after SARS‐CoV‐2 breakthrough infection. JAMA. 2022;327(2):179‐181. 10.1001/jama.2021.22898
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.22898</ArticleId>
            <ArticleId IdType="pmc">PMC8678894</ArticleId>
            <ArticleId IdType="pubmed">34914825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sapkota B, Saud B, Shrestha R, et al. Heterologous prime‐boost strategies for COVID‐19 vaccines. J Travel Med. 2021:taab191. 10.1093/jtm/taab191
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jtm/taab191</ArticleId>
            <ArticleId IdType="pmc">PMC8754745</ArticleId>
            <ArticleId IdType="pubmed">34918097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Augusto G, Mohsen MO, Zinkhan S, Liu X, Vogel M, Bachmann MF. In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion. Allergy. 2022; 77(1):111‐117. 10.1111/all.15065
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/all.15065</ArticleId>
            <ArticleId IdType="pmc">PMC8652796</ArticleId>
            <ArticleId IdType="pubmed">34453338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Callaway E. Omicron likely to weaken COVID vaccine protection. Nature. Published online December 8, 2021. 10.1038/d41586-021-03672-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41586-021-03672-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dejnirattisai W, Huo J, Zhou D, et al. Omicron‐B.1.1.529 leads to widespread escape from neutralizing antibody responses. bioRxiv [Preprint]. 2021. December 22, 2021.12.03.471045. 10.1101/2021.12.03.471045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.12.03.471045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
He X, He C, Hong W, Zhang K, Wei X. The challenges of COVID‐19 Delta variant: Prevention and vaccine development. MedComm. 2021; 2(4):846‐854. 10.1002/mco2.95
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mco2.95</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kozlov M. Omicron overpowers key COVID antibody treatments in early tests. Nature. 2021. Dec 21 10.1038/d41586-021-03829-0; https://www.nature.com/articles/d41586-021-03829-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41586-021-03829-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lusvarghi S, Pollett SD, Neerukonda SN, et al. SARS‐CoV‐2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post‐mRNA vaccine booster. bioRxiv [Preprint]. December 28, 2021. 10.1101/2021.12.22.473880
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.12.22.473880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tareq AM, Emran TB, Dhama K, Dhawan M, Tallei TE. mpact of SARS‐CoV‐2 delta variant (B.1.617.2) in surging second wave of COVID‐19 and efficacy of vaccines in tackling the ongoing pandemic. Hum VaccinImmunother. 2021;17:1‐2. 10.1080/21645515.2021.1963601
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2021.1963601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thiruvengadam R, Binayke A, Awasthi A. SARS‐CoV‐2 delta variant: a persistent threat to the effectiveness of vaccines. Lancet Infect Dis. November 23, 2021. 10.1016/S1473-3099(21)00697-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(21)00697-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
VanBlargan L, Errico J, Halfmann P, et al. An infectious SARS‐CoV‐2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Res Sq [Preprint]. 2021. 10.21203/rs.3.rs-1175516/v1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21203/rs.3.rs-1175516/v1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lippi G, Mattiuzzi C, Henry BM. Neutralizing potency of COVID‐19 vaccines against the SARS‐CoV‐2 Omicron (B.1.1.529) variant. J Med Virol. Published online January 5, 2022. 10.1002/jmv.27575
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.27575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Syed AM, Ciling A, Khalid MM, et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS‐CoV‐2 virus‐like particles. medRxiv [Preprint]. January 2, 2022. 10.1101/2021.12.20.21268048
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.12.20.21268048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang SY, Juthani PV, Borges KA, et al. Severe breakthrough COVID‐19 cases in the SARS‐CoV‐2 delta (B.1.617.2) variant era. Lancet Microbe. 2022;3(1):e4‐e5. 10.1016/S2666-5247(21)00306-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2666-5247(21)00306-2</ArticleId>
            <ArticleId IdType="pmc">PMC8641954</ArticleId>
            <ArticleId IdType="pubmed">34901896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Burki TK. Omicron variant and booster COVID‐19 vaccines. Lancet Respir Med. Published Online December 17,  2021;9:e109. 10.1016/S2213-2600(21)00559-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(21)00559-2</ArticleId>
            <ArticleId IdType="pmc">PMC8479299</ArticleId>
            <ArticleId IdType="pubmed">34597533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Edara VV, Manning KE, Ellis M, et al. mRNA‐1273 and BNT162b2 mRNA vaccines have reduced neutralizing ac tivity against the SARS‐CoV‐2 Omicron variant. bioRxiv [Preprint]. 2021. 10.1101/2021.12.20.473557
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.12.20.473557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khan NA, Al‐Thani H, El‐Menyar A. The emergence of new SARS‐CoV‐2 variant (Omicron) and increasing calls for COVID‐19 boosters‐the debate continues. Travel Med Infect Dis. 2021;45:102246. 10.1016/j.tmaid.2021.102246
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tmaid.2021.102246</ArticleId>
            <ArticleId IdType="pmc">PMC8687713</ArticleId>
            <ArticleId IdType="pubmed">34942376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Garcia‐Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA‐based COVID‐19 vaccine boosters induce neutralizing immunity against SARS‐CoV‐2 Omicron variant. medRxiv [Preprint]. 2021. 10.1101/2021.12.14.21267755
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.12.14.21267755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Doria‐Rose NA, Shen X, Schmidt SD, et al. Booster of mRNA‐1273 vaccine reduces SARS‐CoV‐2 Omicron escape from neutralizing antibodies. medRxiv [Preprint]. Published online December 15, 2021. 10.1101/2021.12.15.21267805
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.12.15.21267805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tanne JH. Covid 19: US cases rise amid omicron fears but booster shots offer protection, experts say. BMJ. 2021;375:n3098. 10.1136/bmj.n3098
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n3098</ArticleId>
            <ArticleId IdType="pubmed">34916250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dhama K, Sharun K, Tiwari R, et al. COVID‐19 vaccine hesitancy – reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic. Hum Vaccin Immunother. 2021;17:1‐5. 10.1080/21645515.2021.1926183
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2021.1926183</ArticleId>
            <ArticleId IdType="pmc">PMC7872040</ArticleId>
            <ArticleId IdType="pubmed">33529127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sharun K, Dhama K. COVID‐19 vaccine diplomacy and equitable access to vaccines amid ongoing pandemic. Arch Med Res. 2021;52:761‐763. 10.1016/j.arcmed.2021.04.006
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.arcmed.2021.04.006</ArticleId>
            <ArticleId IdType="pmc">PMC8062433</ArticleId>
            <ArticleId IdType="pubmed">33941393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wouters OJ, Shadlen KC, Salcher‐Konrad M, et al. Challenges in ensuring global access to COVID‐19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397(10278):1023‐1034. 10.1016/S0140-6736(21)00306-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(21)00306-8</ArticleId>
            <ArticleId IdType="pmc">PMC7906643</ArticleId>
            <ArticleId IdType="pubmed">33587887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS‐CoV‐2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nature Med. Published online January 19,  2022. 10.1038/s41591-021-01678-y
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-021-01678-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ma C, Chen X, Mei F, et al. Drastic decline in sera neutralization against SARS‐CoV‐2 Omicron variant in Wuhan COVID‐19 convalescents. Emerg Microbes Infect. 2022:1‐17. 10.1080/22221751.2022.2031311
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/22221751.2022.2031311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS‐CoV‐2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2021;11:1‐24.</Citation>
        </Reference>
        <Reference>
          <Citation>
Gao Y, Cai C, Grifoni A, et al. Ancestral SARS‐CoV‐2‐specific T cells cross‐recognize the Omicron variant. Nature Med. 2022. 10.1038/s41591-022-01700-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-022-01700-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hirabara SM, Serdan TDA, Gorjao R, et al. SARSCOV‐2 variants: differences and potential of immune evasion. Front Cell Infect Microbiol. 2022;11:781429. 10.3389/fcimb.2021.781429
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2021.781429</ArticleId>
            <ArticleId IdType="pmc">PMC8805732</ArticleId>
            <ArticleId IdType="pubmed">35118007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bae EY, Sanders JM, Johns ML, et al. Therapeutic options for coronavirus disease 2019 (COVID‐19): where are we now?
Curr Infect Dis Rep. 2021;23(12):28. 10.1007/s11908-021-00769-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11908-021-00769-8</ArticleId>
            <ArticleId IdType="pmc">PMC8665318</ArticleId>
            <ArticleId IdType="pubmed">34924819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>NIH (2022). COVID‐19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID‐19) Treatment Guidelines. National Institutes of Health. 2021. https://www.covid19treatmentguidelines.nih.gov/. Accessed January 3, 2022. The guidelines for the management of coronavirus disease 2019 developed by the US National Institutes of Health (NIH) that continue to be updated with newly emerging clinical data.</Citation>
        </Reference>
        <Reference>
          <Citation>
Zou H, Yang Y, Dai H, et al. Recent updates in experimental research and clinical evaluation on drugs for COVID‐19 treatment. Front Pharmacol. 2021;12:732403. 10.3389/fphar.2021.732403
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2021.732403</ArticleId>
            <ArticleId IdType="pmc">PMC8646041</ArticleId>
            <ArticleId IdType="pubmed">34880750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Couzin‐Frankel J. Antiviral pills could change pandemic's course. Science. 2021;374(6569):799‐800. 10.1126/science.acx9605
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.acx9605</ArticleId>
            <ArticleId IdType="pubmed">34762459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fan H, Lou F, Fan J, Li M, Tong Y. The emergence of powerful oral anti‐COVID‐19 drugs in the post‐vaccine era. The Lancet Microbe. 2021;3:91. 10.1016/S2666-5247(21)00278-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2666-5247(21)00278-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Graham F. Daily briefing: Pfizer's COVID pill looks promising. Nature. Published online,  2021. 10.1038/d41586-021-03379-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41586-021-03379-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mahase E. Covid‐19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021b;375:n2713. 10.1136/bmj.n2713
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n2713</ArticleId>
            <ArticleId IdType="pubmed">34750163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Parums DV. Editorial: current status of oral antiviral drug treatments for SARS‐CoV‐2 infection in non‐hospitalized patients. Med Sci Monit. 2022;28:e935952. 10.12659/MSM.935952
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12659/MSM.935952</ArticleId>
            <ArticleId IdType="pmc">PMC8729033</ArticleId>
            <ArticleId IdType="pubmed">34972812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Du M. Contact tracing as a measure to combat COVID‐19 and other infectious diseases highlights. Am J Infect Control. Published online December 8, 2021. 10.1016/j.ajic.2021.11.031
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajic.2021.11.031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Günl F, Mecate‐Zambrano A, Rehländer S, Hinse S, Ludwig S, Brunotte L. Shooting at a moving target‐effectiveness and emerging challenges for SARS‐CoV‐2 vaccine development. Vaccines (Basel). 2021;9(10):1052. 10.3390/vaccines9101052
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/vaccines9101052</ArticleId>
            <ArticleId IdType="pmc">PMC8540924</ArticleId>
            <ArticleId IdType="pubmed">34696160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li X. Omicron: call for updated vaccines. J Med Virol. Published online December 20, 2021. 10.1002/jmv.27530
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.27530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fang “Flora” Fang, Shi PY. Omicron: a drug developer's perspective. Emerg Microbes Infect. 2021;11: 1‐10. 10.1080/22221751.2021.2023330
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/22221751.2021.2023330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mohiuddin M, Kasahara K. Investigating the aggressiveness of the COVID‐19 Omicron variant and suggestions for possible treatment options. Respir Med. 2021;191:106716. 10.1016/j.rmed.2021.106716
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rmed.2021.106716</ArticleId>
            <ArticleId IdType="pmc">PMC8668234</ArticleId>
            <ArticleId IdType="pubmed">34923286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wong S‐C, Au AK‐W, Chen H, et al. Transmission of Omicron (B.1.1.529) ‐ SARS‐CoV‐2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID‐19. The Lancet Regional Health ‐ Western Pacific. 2021;00:100360. 10.1016/j.lanwpc.2021.100360
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lanwpc.2021.100360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kutscher E. Preparing for Omicron as a covid veteran. BMJ. 2021;375:n3021. 10.1136/bmj.n3021
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n3021</ArticleId>
            <ArticleId IdType="pubmed">34872924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Le Page M. Stopping coronavirus variants. New Sci. 2021;252(3365):18‐25. 10.1016/S0262-4079(21)02230-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0262-4079(21)02230-2</ArticleId>
            <ArticleId IdType="pmc">PMC8626128</ArticleId>
            <ArticleId IdType="pubmed">34866733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rae M. Omicron: a failure to act with a global focus will continue the proliferation of new variants of covid‐19. BMJ. 2021;375:n3095. 10.1136/bmj.n3095
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n3095</ArticleId>
            <ArticleId IdType="pubmed">34916212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang X, Powell CA.
How to translate the knowledge of COVID‐19 into the prevention of Omicron variants. ClinTransl Med. 2021;11(12):e680. 10.1002/ctm2.680
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ctm2.680</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
